Gallen International Breast Cancer Conference, Ki67 should be included in routine pathology reports for ER-positive HER2-negative T1–2 N0–1 tumors with a more formal evaluation method referring to the IKWG’s recommendations [3,21]. This evidence concerns the gene ERBB2 and breast cancer.